Back to top
more

Inspire Medical Systems (INSP)

(Delayed Data from NYSE)

$231.01 USD

231.01
215,723

-3.18 (-1.36%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $230.86 -0.15 (-0.06%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.

Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up

Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up

Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?

Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.

Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?

Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.

Why You Should Add Inspire Medical (INSP) to Your Portfolio

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?

Community Health's (CYH) first-quarter results are likely to reflect declining beds in services and adjusted admissions.

ICON (ICLR) Gains From New Offerings, Strategic Acquisitions

ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.

Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?

Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract

Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).

UnitedHealth Group (UNH) Tops on Q1 Earnings, Reaffirms EPS View

UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?

The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.